A Phase II Single-Center, Open-Label, Safety and Efficacy Study of Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation
Latest Information Update: 20 Nov 2023
At a glance
- Drugs Melphalan (Primary)
- Indications Amyloid light-chain amyloidosis; Amyloidosis
- Focus Adverse reactions
- 01 Nov 2023 Results assessing safety and efficacy of propylene glycol-free melphalan (PGF-Mel) during HDM/SCT in patients with AL amyloidosis published in the Transplantation and Cellular Therapy
- 01 Jul 2022 Status changed from recruiting to discontinued.
- 26 Jan 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jul 2022.